Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 4 Interventional

Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen

ClinicalTrials.gov ID: NCT00640627

Public ClinicalTrials.gov record NCT00640627. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo-Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex® (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To compare the safety and efficacy of celecoxib versus placebo in the treatment of patients with knee osteoarthritis who were unresponsive to treatment with prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen

Study identification

NCT ID
NCT00640627
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Enrollment
380 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
40 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 2003 (Type not available)
Primary completion
Not listed
Completion
Sep 2004 (Actual)
Last update posted
Feb 2, 2021

2003 – 2004

United States locations

U.S. sites
30
U.S. states
18
U.S. cities
30
Facility City State ZIP Site status
Pfizer Investigational Site Phoenix Arizona 85051 —
Pfizer Investigational Site Tucson Arizona 85712 —
Pfizer Investigational Site Long Beach California 90806 —
Pfizer Investigational Site Paramount California 90723 —
Pfizer Investigational Site Tustin California 92780 —
Pfizer Investigational Site Colorado Springs Colorado 80904 —
Pfizer Investigational Site Wheat Ridge Colorado 80033 —
Pfizer Investigational Site DeLand Florida 32720 —
Pfizer Investigational Site Naples Florida 34102 —
Pfizer Investigational Site Pembroke Pines Florida 33024 —
Pfizer Investigational Site St. Petersburg Florida 33710 —
Pfizer Investigational Site Woodstock Georgia 30189 —
Pfizer Investigational Site Overland Park Kansas 66215 —
Pfizer Investigational Site New Orleans Louisiana 70119 —
Pfizer Investigational Site Baltimore Maryland 21239 —
Pfizer Investigational Site Flowood Mississippi 39232 —
Pfizer Investigational Site Chesterfield Missouri 63017 —
Pfizer Investigational Site Reno Nevada 89502 —
Pfizer Investigational Site Albuquerque New Mexico 87109 —
Pfizer Investigational Site Mason Ohio 45040 —
Pfizer Investigational Site Beaver Pennsylvania 15009 —
Pfizer Investigational Site Camp Hill Pennsylvania 17011 —
Pfizer Investigational Site Jenkintown Pennsylvania 19046 —
Pfizer Investigational Site Greensboro South Carolina 27401 —
Pfizer Investigational Site Johnson City Tennessee 37601 —
Pfizer Investigational Site Murfreesboro Tennessee 37130 —
Pfizer Investigational Site Nashville Tennessee 37203 —
Pfizer Investigational Site Austin Texas 78705 —
Pfizer Investigational Site San Antonio Texas 78217 —
Pfizer Investigational Site Seattle Washington 98133 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00640627, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2021 · Synced Oct 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00640627 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →